Brain Neurotherapy Bio, Inc.
Clinical trials sponsored by Brain Neurotherapy Bio, Inc., explained in plain language.
A clinical-stage biotech developing cell and gene therapies for neurological disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Gene therapy trial targets rare brain disease
Disease control OngoingThis early-stage trial tests a gene therapy called AAV2-GDNF for multiple system atrophy (MSA), a rare and serious brain disorder. Nine adults with MSA will receive either the gene therapy or a sham surgery. The main goal is to check safety, but researchers will also look for any…
Phase 1 • Sponsor: Brain Neurotherapy Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Gene therapy trial hopes to ease Parkinson's symptoms
Disease control OngoingThis early-stage trial tests a single dose of a gene therapy called AAV2-GDNF, delivered directly into the brain, for people with Parkinson's disease. The main goal is to check safety in 11 adults aged 35-75. Researchers will also look at whether it improves motor symptoms.
Phase 1 • Sponsor: Brain Neurotherapy Bio, Inc. • Aim: Disease control
Last updated Jun 26, 2026 19:13 UTC